Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Blenrep approved by USFDA for use in treatment of relapsed/refractory multiple myeloma
    27 October 2025

    Blenrep approved by USFDA for use in treatment of relapsed/refractory multiple myeloma

    GSK plc announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent.
  • 26 October 2025
    Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
    Avidity is committed to delivering a new class of pioneering RNA therapeutics called Antibody Oligonucleotide Conjugates for serious, genetic neuromuscular diseases. The proposed acquisition will bring Aviditys late-stage neuroscience programs into Novartis and provide Novartis access to a differentiated RNA-targeting delivery platform.
  • 23 October 2025
    Biocon Biologics receives approval of Psoriasis biosmilar in Canada

    Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ I.V., a biosimilar to Stelara® (ustekinumab injection) and Stelara® I.V. (ustekinumab for injection, solution for intravenous infusion). The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October.

  • 23 October 2025
    Cipla got permission to sell Lilly's weight loss medicine
    Eli Lilly and Cipla Limited announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak
  • 15 October 2025
    Lilly's Oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials
    Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin.
  • 15 October 2025
    Molecular markers and risk models guide precision care in liver cancer surgery
    Liver cancer remains one of the worlds most lethal cancers, ranking as the third leading cause of cancer-related deaths. Although surgical advances have improved safety, recurrence after hepatectomy continues to be a major challenge.
  • 15 October 2025
    Ateneo scientists research potential anti-ulcer vaccine
    Since ancient times, it was thought that painful stomach ulcers were caused by eating spicy foods or having an unhealthy diet. But since then, researchers have found that Helicobacter pylori a common bacterium found in over 60% of the world’s population—was the real culprit behind most stomach ulcers and a high risk for stomach cancer.
  • 14 October 2025
    AstraZeneca Reaches Landmark Agreement with Trump Administration to Cut U.S. Drug Prices, Invest 50 Billion USD in Domestic Manufacturing

    AstraZeneca has announced a historic agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients while maintaining the nation’s leadership in biopharmaceutical innovation.

    At a White House event, AstraZeneca CEO Pascal Soriot joined President Trump and senior officials to confirm that the company has voluntarily met all four requests outlined in the President’s July 31 letter. The agreement enables American patients to access AstraZeneca medicines at prices aligned with those in other wealthy nations.

  • 11 October 2025
    IDMA 3rd National cGMP Day 2025 organized by Saveetha College of Pharmacy

    Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai; with a focus on strengthening compliance and promote a culture of quality within the pharmaceutical industry and academia; observed and celebrated theIndian Drug Manufacturers Association (IDMA)3rd National Current Good Manufacturing Practices (cGMP) Dayjointly in association with the Indian Pharmaceutical Association (IPA) Hospital Pharmacy Division, held on October 10, 2025; by organizing an Expert Talk and cGMP Sensitizing Program emphasizing the critical role of current Good Manufacturi

  • 11 October 2025
    FDA Confirms DEG / EG contaminated cough syrups in India, Not exported to U.S.
    The U.S. Food and Drug Administration (FDA) has acknowledged reports of severe and ongoing contamination involving diethylene glycol (DEG) and ethylene glycol (EG) in children’s cough and cold medicines in India. The agency confirmed that these contaminated products have not been shipped to the United States.
Subscribe to Pharma News